T1	Participants 1008 1063	1408 women, 1309 (93%) received OH, and 99 (7%) had LH.
T2	Participants 579 685	multicenter ASTEC (A Study in the Treatment of Endometrial Cancer) randomized controlled trial (1998-2005)
T3	Participants 698 756	Women with presumed early endometrial cancer were included
